

Special Issue

Gender Medicine and Pharmacology

Message from the Guest Editors

Regarding sex, differences in pathophysiology, disease incidence, drug pharmacodynamics/kinetics, response to treatment and related toxicity have been reported. However, several clinical trials have reported an underrepresentation of women, and, in clinical settings, data regarding sex are rarely reported. In women, factors such as body size and composition, hormonal variations, metabolism and access to care systems and therapy could strongly influence pharmacological management and treatment outcomes. In terms of the incidence and prevalence of many diseases, differences between the two sexes play an important role in terms of risk factors. The application of a gender approach from the beginning should be a pivotal tool to optimize treatment in each patient, for each condition. The Special Issue “Gender medicine and pharmacology” will focus on differences at the molecular, cellular and genetic levels in terms of incidence, pathology, physiology and treatment between genders: male, female and genderfluid people. This Special Issue is open for basic to clinical research, or multi-disciplinary approaches.

Guest Editors

Dr. Sarah Allegra

Department of Biological and Clinical Sciences, University of Turin, S. Luigi Gonzaga Hospital, 10043 Orbassano, Italy

Dr. Silvia De Francia

Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Italy

Deadline for manuscript submissions

closed (25 August 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/100128

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).